CNSP
MaterialsCns Pharmaceuticals Inc
$6.90-0.25 (-3.50%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CNSP Today?
No stock-specific AI insight has been generated for CNSP yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$6M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume583K
Avg Volume (10D)—
Shares Outstanding811K
CNSP News
20 articles- Top Midday GainersYahoo Finance·May 4, 2026
- CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement FinancingYahoo Finance·May 4, 2026
- CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology PipelineYahoo Finance·Mar 11, 2026
- CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership TeamYahoo Finance·Mar 2, 2026
- CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic TransformationYahoo Finance·Feb 17, 2026
- CNS Pharmaceuticals Issues Letter to ShareholdersYahoo Finance·Jan 27, 2026
- CNS Pharmaceuticals Announces CEO TransitionYahoo Finance·Dec 17, 2025
- CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 17, 2025
- CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual MeetingYahoo Finance·Nov 10, 2025
- CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmapYahoo Finance·Sep 13, 2025
- CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 3, 2025
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.Yahoo Finance·Aug 27, 2025
- JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025Yahoo Finance·Aug 15, 2025
- CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Aug 15, 2025
- CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechYahoo Finance·Aug 14, 2025
- CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand ConferenceYahoo Finance·Jul 22, 2025
- JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now LiveYahoo Finance·Jul 22, 2025
- JTC Team Announces Participating Line Up for the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand ConferenceYahoo Finance·Jul 18, 2025
- CNS Pharmaceuticals Announces Reverse Stock SplitYahoo Finance·Jul 18, 2025
- CNS Pharmaceuticals Participates in Virtual Investor CEO Connect SegmentYahoo Finance·Jul 9, 2025
All 20 articles loaded
Price Data
Open$5.71
Previous Close$7.15
Day High$7.30
Day Low$5.27
52 Week High—
52 Week Low—
Fundamentals
Market Cap$6M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume583K
Avg Volume (10D)—
Shares Outstanding811K
About Cns Pharmaceuticals Inc
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—